The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so for ER positive triple uh ER positive her2 negative breast cancer is the most common kind the most important drug therapy relate to anti-estrogen medicines so there are two basic flavors in the early stage one is called tamoxifen the other is called an aromatase inhibitor
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so for ear positive her to negative breast cancers the most common kind the most important drug therapy relate to anti-estrogen medicines so there are two basic flavors in the early stage one is called tamoxifen the other is called called an aromatase inhibitor
and so for cancers of almost any size that are estrogen receptor positive we think about anti-estrogen medicines like tamoxifen or aromatase inhibitors for tumors that are as small as a half a centimeter or more uh in size we think about drugs like trastuzamab that Target her too and similarly for very small triple negative breast cancers we often think about chemotherapy